Literature DB >> 17941342

Cognitive phenotypes in Alzheimer's disease and genetic risk.

Julie S Snowden1, Cheryl L Stopford, Camille L Julien, Jennifer C Thompson, Yvonne Davidson, Linda Gibbons, Antonia Pritchard, Corinne L Lendon, Anna M Richardson, Anoop Varma, David Neary, David Mann.   

Abstract

Variation in the clinical characteristics of patients with Alzheimer's disease (AD) is increasingly recognised, although the factors underlying variation are not fully understood. The study examined the cognitive characteristics of 523 AD patients at the time of their presentation to a neurological dementia clinic and explored the relationship to family history and apolipoprotein E (APOE) genotype. Distinct profiles were identified, which were mirrored by topographical differences on neuroimaging. Clinical distinctions were maintained over time. Two-thirds of patients showed a constellation of deficits at presentation which included memory, language, visuospatial and constructional difficulties. However, a quarter had circumscribed presentations of amnesia, aphasia, perceptuospatial disorder or apraxia. The rare presence of frontal lobe characteristics was associated with a younger age of onset, an increased incidence of myoclonus at presentation, a positive family history but not with possession of APOE epsilon4 allele. An amnestic presentation (severe, yet circumscribed amnesia) was strongly associated with an older age of onset, a positive family history and the presence of APOE epsilon4 allele. Posterior cortical presentations showed a female bias, were typically sporadic, and showed no association with APOE epsilon4. The findings support the notion of phenotypic variation in AD, and show that genetic risk factors can influence clinical presentation. The findings draw attention to the specific association between APOE epsilon4 allele and memory but challenge the commonly held notion that the presence of the epsilon4 allele inevitably reduces onset age. The findings indicate that risk factors other than APOE epsilon4 allele underlie the non-familial, early onset posterior hemisphere presentations of AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941342     DOI: 10.1016/s0010-9452(08)70683-x

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  92 in total

1.  Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors.

Authors:  Jesse Mez; Stephanie Cosentino; Adam M Brickman; Edward D Huey; Jennifer J Manly; Richard Mayeux
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

2.  Homonymous Hemianopsia Due to Posterior Cortical Atrophy.

Authors:  Francesco Pellegrini; Andrew G Lee; Pietro Zucchetta
Journal:  Neuroophthalmology       Date:  2017-02-15

3.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Authors:  Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan
Journal:  Ann Neurol       Date:  2016-11-07       Impact factor: 10.422

5.  Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset.

Authors:  Josephine Barnes; Bradford C Dickerson; Chris Frost; Lize C Jiskoot; David Wolk; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

6.  Non-pharmacological intervention for posterior cortical atrophy.

Authors:  Agnès Weill-Chounlamountry; Jorge Alves; Pascale Pradat-Diehl
Journal:  World J Clin Cases       Date:  2016-08-16       Impact factor: 1.337

7.  An exploration of cognitive subgroups in Alzheimer's disease.

Authors:  Julie E Davidson; Michael C Irizarry; Bethany C Bray; Sally Wetten; Nicholas Galwey; Rachel Gibson; Michael Borrie; Richard Delisle; Howard H Feldman; Ging-Yuek Hsiung; Luis Fornazzari; Serge Gauthier; Danilo Guzman; Inge Loy-English; Ron Keren; Andrew Kertesz; Peter St George-Hyslop; John Wherrett; Andreas U Monsch
Journal:  J Int Neuropsychol Soc       Date:  2009-12-04       Impact factor: 2.892

8.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Authors:  Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust
Journal:  Brain       Date:  2010-01-15       Impact factor: 13.501

Review 9.  Posterior Cortical Atrophy.

Authors:  Jonathan M Schott; Sebastian J Crutch
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 10.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.